#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.
In this highly technical episode, lipidologist Tom Dayspring joins Peter Attia to explore the intricate relationship between cholesterol metabolism and brain health. They discuss why the brain's cholesterol system operates almost entirely independently from the rest of the body, using apoE rather than apoB. Dayspring explains how APOE genotype—particularly the APOE4 allele—is the strongest genetic risk factor for late-onset Alzheimer's disease, influencing amyloid and tau pathology. The conversation also reviews what is known about the effects of statins, ezetimibe, omega-3 fatty acids, and CETP inhibitors on brain health. This episode provides a crucial framework for understanding the often misunderstood link between lipid-lowering therapies and neurodegenerative risk.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Canon
•
APOE Genotype and Alzheimer's Risk
APOE genotype is the strongest genetic risk factor for late-onset Alzheimer's disease, with the APOE4 allele significantly increasing risk and APOE2 being protective.
Dayspring reinforces that apoB-containing lipoproteins, rather than LDL cholesterol per se, are the causative agents in atherosclerotic plaque formation, and lowering apoB is the cornerstone of cardiovascular risk reduction.
The Brain's Cholesterol System Is Independent00:29:00
Dayspring explains that the brain operates its own cholesterol production and transport system, using apolipoprotein E (apoE) instead of apoB, and this system is largely separate from cholesterol circulating in the bloodstream.
Lowering LDL Cholesterol Does Not Starve the Brain00:11:45
A common fear is that aggressively lowering cholesterol with statins or other drugs could deprive the brain of cholesterol, but Dayspring clarifies that the brain's self-contained cholesterol system makes this concern unfounded.
Lipid-Lowering Therapies and Brain Health: Evidence Remains Mixed
The episode reviews what is known about the effects of statins, ezetimibe, omega-3s, and CETP inhibitors on brain health, concluding that current evidence does not support major cognitive harm, but also hasn't shown robust protection against dementia.